These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 36373407)

  • 1. A model based on machine learning for the prediction of cyclosporin A trough concentration in Chinese allo-HSCT patients.
    Song L; Huang CR; Pan SZ; Zhu JG; Cheng ZQ; Yu X; Xue L; Xia F; Zhang JY; Wu DP; Miao LY
    Expert Rev Clin Pharmacol; 2023 Jan; 16(1):83-91. PubMed ID: 36373407
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Population pharmacokinetics of cyclosporine in Chinese children receiving hematopoietic stem cell transplantation.
    Li TF; Hu L; Ma XL; Huang L; Liu XM; Luo XX; Feng WY; Wu CF
    Acta Pharmacol Sin; 2019 Dec; 40(12):1603-1610. PubMed ID: 31341257
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Initial dosage optimisation of cyclosporine in Chinese paediatric patients undergoing allogeneic haematopoietic stem cell transplantation based on population pharmacokinetics: a retrospective study.
    Feng H; Wang X; Zheng W; Liu S; Jiang H; Lin Y; Qiu H; Chan TF; Huang M; Li Y; Mo X; Li J
    BMJ Paediatr Open; 2023 Aug; 7(1):. PubMed ID: 37643815
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Population pharmacokinetics of cyclosporine A based on NONMEM in Chinese allogeneic hematopoietic stem cell transplantation recipients.
    Zhou H; Gao Y; Cheng XL; Li ZD
    Eur J Drug Metab Pharmacokinet; 2012 Dec; 37(4):271-8. PubMed ID: 22446981
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cyclosporine A trough concentrations are associated with acute GvHD after non-myeloablative allogeneic hematopoietic cell transplantation.
    de Kort EA; de Lil HS; Bremmers MEJ; van Groningen LFJ; Blijlevens NMA; Huls G; Brüggemann RJM; van Dorp S; van der Velden WJFM
    PLoS One; 2019; 14(3):e0213913. PubMed ID: 30897127
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of cyclosporine-A concentration in T-cell replete haploidentical allogeneic stem cell transplantation.
    Yang X; Yang S; Sun A; Qiu H; Tang X; Han Y; Wu D
    Clin Transplant; 2018 Apr; 32(4):e13220. PubMed ID: 29493007
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Population pharmacokinetics of ciclosporin in allogeneic hematopoietic stem cell transplant recipients: C-reactive protein as a novel covariate for clearance.
    Ling J; Yang XP; Dong LL; Jiang Y; Zou SL; Hu N; Chen R
    J Clin Pharm Ther; 2022 Apr; 47(4):483-492. PubMed ID: 34779003
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Population pharmacokinetics and individualized dosage prediction of cyclosporine in allogeneic hematopoietic stem cell transplant patients.
    Xue L; Zhang WW; Ding XL; Zhang JJ; Bao JA; Miao LY
    Am J Med Sci; 2014 Dec; 348(6):448-54. PubMed ID: 25247760
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Population pharmacokinetics of ciclosporin in haematopoietic allogeneic stem cell transplantation with emphasis on limited sampling strategy.
    Wilhelm AJ; de Graaf P; Veldkamp AI; Janssen JJ; Huijgens PC; Swart EL
    Br J Clin Pharmacol; 2012 Apr; 73(4):553-63. PubMed ID: 21988410
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of polymorphism of
    Wang L; Zeng G; Li J; Luo J; Li H; Zhang Z
    Xenobiotica; 2021 Jul; 51(7):852-858. PubMed ID: 33974505
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Population pharmacokinetics of cyclosporine in hematopoietic stem cell transplant patients: consideration of genetic polymorphisms.
    Kim MG; Kim IW; Choi B; Han N; Yun HY; Park S; Oh JM
    Ann Pharmacother; 2015 Jun; 49(6):622-30. PubMed ID: 25818517
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Cytomegalovirus infection and immunosuppressant treatment in allogeneic hematopoietic stem cell transplantation recipients].
    Xie W; Zhang X; Peng G; Yi B; Liu W; Zhong B; Jian Z; Fan Y
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2010 Nov; 35(11):1162-6. PubMed ID: 21131738
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patient-based prediction algorithm of relapse after allo-HSCT for acute Leukemia and its usefulness in the decision-making process using a machine learning approach.
    Fuse K; Uemura S; Tamura S; Suwabe T; Katagiri T; Tanaka T; Ushiki T; Shibasaki Y; Sato N; Yano T; Kuroha T; Hashimoto S; Furukawa T; Narita M; Sone H; Masuko M
    Cancer Med; 2019 Sep; 8(11):5058-5067. PubMed ID: 31305031
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Achievement of target cyclosporine concentrations as a predictor of severe acute graft versus host disease in children undergoing hematopoietic stem cell transplantation and receiving cyclosporine and methotrexate prophylaxis.
    Punnett A; Sung L; Price V; Das P; Diezi M; Doyle J; Dupuis LL
    Ther Drug Monit; 2007 Dec; 29(6):750-7. PubMed ID: 18043472
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prediction of Allogeneic Hematopoietic Stem-Cell Transplantation Mortality 100 Days After Transplantation Using a Machine Learning Algorithm: A European Group for Blood and Marrow Transplantation Acute Leukemia Working Party Retrospective Data Mining Study.
    Shouval R; Labopin M; Bondi O; Mishan-Shamay H; Shimoni A; Ciceri F; Esteve J; Giebel S; Gorin NC; Schmid C; Polge E; Aljurf M; Kroger N; Craddock C; Bacigalupo A; Cornelissen JJ; Baron F; Unger R; Nagler A; Mohty M
    J Clin Oncol; 2015 Oct; 33(28):3144-51. PubMed ID: 26240227
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Toward optimization of cyclosporine concentration target to prevent acute graft-versus-host disease following myeloablative allogeneic stem cell transplant.
    Kwan ACF; Blosser N; Ghosh S; Leyshon C; Dersch-Mills D; Puckrin R; Duggan P; Zepeda V; Savoie L; Stewart D; Storek J; Jamani K
    Clin Transplant; 2022 Aug; 36(8):e14732. PubMed ID: 35606904
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Everolimus in combination with cyclosporin a as pre- and posttransplantation immunosuppressive therapy in nonmyeloablative allogeneic hematopoietic stem cell transplantation.
    Junghanss C; Rathsack S; Wacke R; Weirich V; Vogel H; Drewelow B; Mueller S; Altmann S; Freund M; Lange S
    Biol Blood Marrow Transplant; 2012 Jul; 18(7):1061-8. PubMed ID: 22182476
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Population pharmacokinetic model to predict steady-state exposure to once-daily cyclosporin microemulsion in renal transplant recipients.
    Schädeli F; Marti HP; Frey FJ; Uehlinger DE
    Clin Pharmacokinet; 2002; 41(1):59-69. PubMed ID: 11825097
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Addition of sirolimus to standard cyclosporine plus mycophenolate mofetil-based graft-versus-host disease prophylaxis for patients after unrelated non-myeloablative haemopoietic stem cell transplantation: a multicentre, randomised, phase 3 trial.
    Sandmaier BM; Kornblit B; Storer BE; Olesen G; Maris MB; Langston AA; Gutman JA; Petersen SL; Chauncey TR; Bethge WA; Pulsipher MA; Woolfrey AE; Mielcarek M; Martin PJ; Appelbaum FR; Flowers MED; Maloney DG; Storb R
    Lancet Haematol; 2019 Aug; 6(8):e409-e418. PubMed ID: 31248843
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Using a machine learning algorithm to predict acute graft-versus-host disease following allogeneic transplantation.
    Arai Y; Kondo T; Fuse K; Shibasaki Y; Masuko M; Sugita J; Teshima T; Uchida N; Fukuda T; Kakihana K; Ozawa Y; Eto T; Tanaka M; Ikegame K; Mori T; Iwato K; Ichinohe T; Kanda Y; Atsuta Y
    Blood Adv; 2019 Nov; 3(22):3626-3634. PubMed ID: 31751471
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.